Diamond Hill Capital Management Inc. increased its holdings in shares of Perrigo Company plc (NYSE:PRGO – Free Report) by 38.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,481,711 shares of the company’s stock after purchasing an additional 683,965 shares during the quarter. Diamond Hill Capital Management Inc.’s holdings in Perrigo were worth $34,545,000 as of its most recent filing with the SEC.
A number of other large investors have also bought and sold shares of PRGO. Amundi increased its stake in Perrigo by 11.7% during the 1st quarter. Amundi now owns 5,292 shares of the company’s stock worth $148,000 after purchasing an additional 556 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Perrigo by 126.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock worth $32,520,000 after purchasing an additional 647,982 shares in the last quarter. United Services Automobile Association bought a new stake in Perrigo during the 1st quarter worth approximately $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Perrigo by 6.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,112 shares of the company’s stock worth $14,388,000 after acquiring an additional 32,151 shares in the last quarter. Finally, Geneos Wealth Management Inc. grew its stake in shares of Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after acquiring an additional 786 shares in the last quarter. 95.91% of the stock is owned by institutional investors.
Perrigo Price Performance
NYSE:PRGO opened at $11.35 on Friday. Perrigo Company plc has a 1-year low of $9.23 and a 1-year high of $28.43. The company has a current ratio of 2.72, a quick ratio of 1.59 and a debt-to-equity ratio of 1.45. The firm has a fifty day simple moving average of $10.80 and a 200 day simple moving average of $12.85. The stock has a market capitalization of $1.57 billion, a PE ratio of -0.87, a P/E/G ratio of 1.31 and a beta of 0.52.
Perrigo Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 16th. Investors of record on Friday, May 29th will be paid a $0.29 dividend. The ex-dividend date of this dividend is Friday, May 29th. This represents a $1.16 annualized dividend and a dividend yield of 10.2%. Perrigo’s dividend payout ratio (DPR) is currently -8.85%.
Analyst Ratings Changes
Several brokerages recently commented on PRGO. Jefferies Financial Group restated a “hold” rating on shares of Perrigo in a report on Thursday, February 26th. Canaccord Genuity Group reduced their target price on shares of Perrigo from $20.00 to $17.00 and set a “buy” rating for the company in a report on Friday, February 27th. Weiss Ratings upgraded shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Finally, Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $19.33.
Check Out Our Latest Research Report on PRGO
About Perrigo
Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.
Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.
See Also
- Five stocks we like better than Perrigo
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Want to see what other hedge funds are holding PRGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perrigo Company plc (NYSE:PRGO – Free Report).
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.
